DGX is poised for solid Q3 2025 results, backed by strong DIS growth, strategic M&A and robust test demand across key health segments.

Blood test to aid cancer treatment and recurrence monitoring now available from a German lab for potentially faster results ...

A cancer treatment laboratory in Lewisville recently made a medical breakthrough that could greatly decrease the risk of the ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Quest Diagnostics (DGX) reports results for ...

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of ...

Finnish health tech company Oura has raised $900 million in fresh funding led by Fidelity Management & Research Company, with ...

| The third quarter of 2025 saw 15 new hospital transaction announcements, more than doubling the first half's total, ...

A QHIN and interoperability pro explains what clean, standardized and interoperable data enables with AI. He also details ...

The race is on to harness the near-infinite power of nuclear fusion—by building a star on Earth. And scientists are closer ...

The Health Facilities Regulatory Agency (HeFRA) has shut down 18 health facilities in the Ashanti Region for operating below acceptable standards ...